Alector ALEC 深 滬
交易中 07-23 11:32:55 美东时间
1.525
-0.005
-0.33%
華盛通- 最 高1.545
- 今 開1.48
- 成交量 34.23万股
- 最 低 1.47
- 昨 收 1.53
- 總市值 1.69亿
- 52周最高 3.3999
- 市盈率 靜 --
- 換手率 0.31%
- 52周最低 1.09
- 委 比 38.89%
- 總股本 1.11亿
- 歷史最高 43.32
- 量 比 2.51
- 振 幅 4.90%
- 歷史最低 0.87
- 每 手 1
- 風險率 0.55%
個股概要
財務分析
公司資料
相關新聞
分紅派息
- 分時圖
- 日k
- 周k
- 月k
相關新聞
更多Alector Ends GSK Collaboration, Retires Hercules Capital Debt
Alector ( ($ALEC) ) has provided an announcement. On October 21, 2025, Alector ...
07-09 04:32
GSK Terminates Collaboration, License Agreement With Alector, Effective Jan. 2, 2027; Alector Repays $10.429M
https://www.sec.gov/ix?doc=/Archives/edgar/data/1653087/000119312526298526/alec-20260706.htm
07-09 04:20
Rani Therapeutics Appoints Nicholas Maestas as Chief Financial Officer
Rani Therapeutics appoints Nicholas Maestas as Chief Financial Officer, effective immediately. Maestas brings over 10 years of financial leadership experience in biotechnology, including roles at Tempest Therapeutics and Alector. He succeeds Svai Sanford, who is departing for another opportunity. Maestas expressed enthusiasm for advancing Rani's oral delivery platform technology, RaniPill®, to address the challenge of effective oral delivery of b...
06-29 12:00
Alector shares are trading lower after the company reported worse-than-expected Q1 sales results.
Alector shares are trading lower after the company reported worse-than-expected...
05-08 23:24
Alector Launches Up To $125M At-The-Market Common Stock Offering Through TD Cowen
$125,000,000Common StockWe have entered into a sales agreement with TD Securities (USA) LLC ("TD Cowen") relating to shares of our common stock offered by this prospectus supplement and the accompanying prospectus. In
05-08 06:09
Alector Q1 EPS $(0.21) Beats $(0.35) Estimate, Sales $1.046M Miss $6.207M Estimate
Alector (NASDAQ:ALEC) reported quarterly losses of $(0.21) per share which beat the analyst consensus estimate of $(0.35) by 40 percent. This is a 48.78 percent increase over losses of $(0.41) per share from the same
05-08 04:34
GSK licenses Halozyme's Enhanze drug delivery technology
Halozyme Therapeutics (HALO) announced on Thursday that GSK (GSK) has reached an agreement to license its Enhanze drug delivery technology to advance subcutaneously delivered cancer drugs. The compani...
05-08 01:01
Alector Reports First Quarter 2026 Financial Results and Provides Business Update
Alector reported Q1 2026 financial results with $206.5 million in cash, supporting operations through 2027. The company advanced its Alector Brain Carrier (ABC) platform across multiple modalities, including antibodies, enzymes, and siRNA. Key programs include AL037/AL137 (ABC-enabled anti-amyloid beta antibody for Alzheimer’s), AL050 (ABC-enabled GCase ERT for Parkinson’s), and AL064/AL164 (ABC-enabled tau siRNA for Alzheimer’s and tauopathies)....
05-07 20:05
Alector halts mid-stage trial for Alzheimer’s candidate developed with GSK
Alector (ALEC) shares rose ~5% on Thursday after the neurology-focused biotech announced its decision to discontinue a mid-stage trial for latozinemab, an experimental therapy developed with GSK (GSK)...
05-01 02:01
